ALDX Logo

Aldeyra Therapeutics, Inc. (ALDX) 

NASDAQ
Market Cap
$193.1M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
89 of 809
Rank in Industry
68 of 445

Largest Insider Buys in Sector

ALDX Stock Price History Chart

ALDX Stock Performance

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Insider Activity of Aldeyra Therapeutics, Inc.

Over the last 12 months, insiders at Aldeyra Therapeutics, Inc. have bought $2.77M and sold $5.18M worth of Aldeyra Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Aldeyra Therapeutics, Inc. have bought $12.66M and sold $5.18M worth of stock each year.

Highest buying activity among insiders over the last 12 months: PERCEPTIVE ADVISORS LLC (10 percent owner) — $47.06M.

The last purchase of 37,712 shares for transaction amount of $178,755 was made by PERCEPTIVE ADVISORS LLC (10 percent owner) on 2024‑04‑05.

List of Insider Buy and Sell Transactions, Aldeyra Therapeutics, Inc.

2024-04-05PurchasePERCEPTIVE ADVISORS LLC10 percent owner
37,712
0.0643%
$4.74$178,755-16.53%
2024-04-04PurchasePERCEPTIVE ADVISORS LLC10 percent owner
140,281
0.2374%
$4.67$655,112-15.81%
2024-04-03PurchasePERCEPTIVE ADVISORS LLC10 percent owner
309,847
0.5185%
$4.09$1.27M-5.06%
2024-04-02PurchasePERCEPTIVE ADVISORS LLC10 percent owner
186,051
0.3061%
$3.44$640,015+10.99%
2024-04-01PurchasePERCEPTIVE ADVISORS LLC10 percent owner
8,374
0.0141%
$3.25$27,216+20.49%
2024-03-12SaleBrady Todd CPresident and CEO
85,324
0.147%
$3.05$260,238+29.07%
2024-03-12SaleMachatha StephenChief Development Officer
11,537
0.0206%
$3.16$36,503+29.07%
2024-03-11SaleBrady Todd CPresident and CEO
97,914
0.1675%
$3.27$320,521+19.38%
2024-03-11SaleMachatha StephenChief Development Officer
18,231
0.0324%
$3.41$62,102+19.38%
2024-03-11SaleGreenberg BruceSee Remarks
13,201
0.0235%
$3.41$44,968+19.38%
2023-10-18SalePERCEPTIVE ADVISORS LLC10 percent owner
306,499
0.5276%
$1.74$533,308+93.93%
2023-10-16SalePERCEPTIVE ADVISORS LLC10 percent owner
2.45M
3.6657%
$1.60$3.92M+83.06%
2022-08-09PurchaseEDELMAN JOSEPH
15,000
0.027%
$7.85$117,750-4.83%
2022-08-08PurchaseEDELMAN JOSEPH
97,000
0.1669%
$7.24$702,280-1.53%
2022-08-05PurchaseEDELMAN JOSEPH
141,000
0.2422%
$6.95$979,950+2.46%
2022-08-04PurchaseEDELMAN JOSEPH
95,100
0.1609%
$6.17$586,767+13.46%
2022-08-03PurchaseEDELMAN JOSEPH
100,000
0.1722%
$5.84$584,000+21.64%
2022-08-02PurchaseEDELMAN JOSEPH
412,406
0.6992%
$5.59$2.31M+24.82%
2022-08-01PurchaseEDELMAN JOSEPH
144,185
0.2447%
$5.05$728,134+38.21%
2022-07-29PurchaseEDELMAN JOSEPH
222,123
0.3792%
$5.03$1.12M+39.29%

Insider Historical Profitability

18.59%
PERCEPTIVE ADVISORS LLC10 percent owner
9275851
14.6095%
$3.25182+4.58%
Brady Todd CPresident and CEO
1471298
2.0682%
$3.25112+8.55%
Machatha StephenChief Development Officer
252812
0.4134%
$3.2502
Greenberg BruceSee Remarks
130154
0.2049%
$3.2501
EDELMAN JOSEPH
11350085
19.2956%
$3.2590+19.29%
DOUGLAS RICHARDdirector
125000
0.2125%
$3.2570+43%
Reed JoshuaChief Financial Officer
35774
0.0608%
$3.2510+5.74%
JOYCE MARTIN JOSEPH
23967
0.0407%
$3.2550+39.85%
Bronstein Bendirector
18644
0.0317%
$3.2530+4.21%
Clark David JChief Medical Officer
17878
0.0304%
$3.2510+8.52%
Clarke C. Boyddirector
15500
0.0264%
$3.2520+69.19%
Phillips Gary M.director
9375
0.0159%
$3.2510+20.66%
TREU JESSE Idirector
8763
0.0149%
$3.2501
Walker Nealdirector
6250
0.0106%
$3.2510+20.66%
McMullin DavidChief Commerical Officer
6148
0.0105%
$3.2510+5.74%
Tulipano Stephen JChief Financial Officer
3333
0.0057%
$3.2510+0.98%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Perceptive Advisors$28.1M14.468.59M0%+$00.02
Tupelo Capital Management LLC$17.9M9.225.48M0%+$011.71
The Vanguard Group$12.65M6.513.87M-1.49%-$191,353.86<0.0001
BlackRock$10.83M5.573.31M-3.5%-$392,357.51<0.0001
Kennedy Capital Management Inc$4.31M2.221.32M+3.29%+$137,369.430.09
Geode Capital Management$3.36M1.731.03M+0.55%+$18,399.16<0.0001
HERITAGE ASSET MANAGEMENT INC$3.16M1.63967,815-4.21%-$139,037.130.02
Verition Fund Management Llc$3.08M1.58940,398-29.02%-$1.26M0.03
State Street$3.07M1.58939,569+4.51%+$132,631.22<0.0001
Dimensional Fund Advisors$2.88M1.49882,210-15.06%-$511,565.39<0.01
Renaissance Technologies$2.38M1.23727,690+142.56%+$1.4M<0.01
D. E. Shaw & Co.$1.79M0.92547,640+110.58%+$940,399.79<0.01
Acadian Asset Management$1.48M0.76452,449+106.33%+$761,685.370.01
Bank of America$1.3M0.67398,951+6.69%+$81,851.32<0.0001
Northern Trust$1.27M0.66389,187-0.97%-$12,491.40<0.0001
Millennium Management LLC$1.27M0.65388,705-11.74%-$169,003.36<0.01
Wells Fargo$1.27M0.65387,304+12.22%+$137,964.56<0.0001
Los Angeles Capital Management LLC$1.25M0.64380,773+240.85%+$879,829.68<0.01
Two Sigma Advisers LP$1.23M0.63374,900+6.69%+$76,845.00<0.01
Morgan Stanley$1.14M0.59349,546-16.79%-$230,606.86<0.0001
Johnson & Johnson$979,918.000.5299,6690%+$00.02
Deutsche Bank$956,105.000.49292,387-1.7%-$16,510.22<0.0001
Two Sigma$781,412.000.4238,964+18.57%+$122,373.17<0.01
Palo Alto Investors Lp$737,271.000.38225,4650%+$00.08
Jacobs Levy Equity Management$585,065.000.3178,919New+$585,065.00<0.01
Woodstock Corporation$558,238.000.29170,715+46.28%+$176,615.950.06
BNY Mellon$525,938.000.27160,837-5.41%-$30,090.60<0.0001
Nuveen$424,197.000.22129,7240%+$0<0.0001
Ameriprise Financial$412,595.000.21126,176-23.96%-$129,988.88<0.0001
Charles Schwab$410,467.000.21125,5250%+$0<0.0001
Sherbrooke Park Advisers Llc$352,336.000.18107,748New+$352,336.000.07
AQR Capital$343,527.000.18105,054New+$343,527.00<0.01
Simplex Trading Llc$305,000.000.1693,465+333.15%+$234,585.510.01
Goldman Sachs$299,915.000.1591,717-37.81%-$182,345.26<0.0001
Ohio Strs$269,000.000.1482,300-5.94%-$16,996.35<0.01
RhumbLine Advisers$209,512.000.1164,074+3.57%+$7,229.63<0.0001
Cornercap Investment Counsel Inc$201,435.000.161,6010%+$00.03
International Assets Investment Management Llc$197,181.000.160,300+3.08%+$5,886.00<0.01
Citadel Advisors LLC$180,661.000.0955,248-18.43%-$40,812.88<0.0001
AllianceBernstein$164,939.000.0950,4400%+$0<0.0001
UBS$157,993.000.0848,316-8.97%-$15,568.44<0.0001
T. Rowe Price$158,000.000.0848,273+7.69%+$11,278.93<0.0001
Denali Advisors$154,671.000.0847,300New+$154,671.000.05
Susquehanna International Group$130,529.000.0739,917-80.26%-$530,654.00<0.0001
Squarepoint Ops LLC$124,891.000.0638,193-47.66%-$113,701.07<0.0001
Raymond James Associates$117,798.000.0636,024+9.88%+$10,594.76<0.0001
First Manhattan Co.$113,616.000.0634,7450%+$0<0.0001
Barclays$106,000.000.0632,487-49.12%-$102,348.88<0.0001
Invesco$104,071.000.0531,826+0.19%+$199.47<0.0001
Joseph P. Lucia & Associates LLC$92,384.000.0528,2520%+$00.06